194 related articles for article (PubMed ID: 9334743)
21. 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.
Ducrot P; Legraverend M; Grierson DS
J Med Chem; 2000 Nov; 43(22):4098-108. PubMed ID: 11063606
[TBL] [Abstract][Full Text] [Related]
22. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.
Otyepka M; Krystof V; Havlícek L; Siglerová V; Strnad M; Koca J
J Med Chem; 2000 Jun; 43(13):2506-13. PubMed ID: 10891109
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex.
Legraverend M; Tunnah P; Noble M; Ducrot P; Ludwig O; Grierson DS; Leost M; Meijer L; Endicott J
J Med Chem; 2000 Apr; 43(7):1282-92. PubMed ID: 10753466
[TBL] [Abstract][Full Text] [Related]
24. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
25. Structural basis for substrate recognition and control in protein kinases.
Johnson LN
Ernst Schering Res Found Workshop; 2001; (34):47-69. PubMed ID: 11394047
[No Abstract] [Full Text] [Related]
26. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine.
Filgueira de Azevedo W; Gaspar RT; Canduri F; Camera JC; Freitas da Silveira NJ
Biochem Biophys Res Commun; 2002 Oct; 297(5):1154-8. PubMed ID: 12372407
[TBL] [Abstract][Full Text] [Related]
27. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
[TBL] [Abstract][Full Text] [Related]
29. Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe.
Atkinson GE; Cowan A; McInnes C; Zheleva DI; Fischer PM; Chan WC
Bioorg Med Chem Lett; 2002 Sep; 12(18):2501-5. PubMed ID: 12182847
[TBL] [Abstract][Full Text] [Related]
30. Bound to activate: conformational consequences of cyclin binding to CDK2.
Radzio-Andzelm E; Lew J; Taylor S
Structure; 1995 Nov; 3(11):1135-41. PubMed ID: 8591024
[TBL] [Abstract][Full Text] [Related]
31. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717.
Dreyer MK; Borcherding DR; Dumont JA; Peet NP; Tsay JT; Wright PS; Bitonti AJ; Shen J; Kim SH
J Med Chem; 2001 Feb; 44(4):524-30. PubMed ID: 11170642
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of Cdk2/Cyclin E inhibition by p27 and p27 phosphorylation.
Xu X; Nakano T; Wick S; Dubay M; Brizuela L
Biochemistry; 1999 Jul; 38(27):8713-22. PubMed ID: 10393546
[TBL] [Abstract][Full Text] [Related]
33. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.
Johnson LN; De Moliner E; Brown NR; Song H; Barford D; Endicott JA; Noble ME
Pharmacol Ther; 2002; 93(2-3):113-24. PubMed ID: 12191604
[TBL] [Abstract][Full Text] [Related]
34. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
Barvian M; Boschelli DH; Cossrow J; Dobrusin E; Fattaey A; Fritsch A; Fry D; Harvey P; Keller P; Garrett M; La F; Leopold W; McNamara D; Quin M; Trumpp-Kallmeyer S; Toogood P; Wu Z; Zhang E
J Med Chem; 2000 Nov; 43(24):4606-16. PubMed ID: 11101352
[TBL] [Abstract][Full Text] [Related]
35. Crystal structure of cyclin-dependent kinase 2.
De Bondt HL; Rosenblatt J; Jancarik J; Jones HD; Morgan DO; Kim SH
Nature; 1993 Jun; 363(6430):595-602. PubMed ID: 8510751
[TBL] [Abstract][Full Text] [Related]
36. Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching.
Furet P; Meyer T; Mittl P; Fretz H
J Comput Aided Mol Des; 2001 May; 15(5):489-95. PubMed ID: 11394741
[TBL] [Abstract][Full Text] [Related]
37. Picture story. Reining in CDK.
Feng H
Nat Struct Biol; 2001 May; 8(5):391. PubMed ID: 11323710
[No Abstract] [Full Text] [Related]
38. Picture story. Cyclin switch.
Riddihough G
Nat Struct Biol; 1995 Aug; 2(8):636. PubMed ID: 7552724
[No Abstract] [Full Text] [Related]
39. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.
Schoepfer J; Fretz H; Chaudhuri B; Muller L; Seeber E; Meijer L; Lozach O; Vangrevelinghe E; Furet P
J Med Chem; 2002 Apr; 45(9):1741-7. PubMed ID: 11960485
[TBL] [Abstract][Full Text] [Related]
40. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
